Literature DB >> 20559968

The use of magnetic resonance methods in translational cardiovascular research.

Arthur H L From1, Kamil Ugurbil.   

Abstract

Magnetic resonance methods are widely applicable to research questions posed in translational cardiovascular studies. The main intent of this review was to offer the cardiovascular translational research scientist a "menu" of magnetic resonance (MR) approaches that can be applied to answering research questions posed in a variety of experimental situations including those involving the use of human subjects. Obviously, this menu is not comprehensive and many other topics could have been selected for emphasis. However, we hope that the material presented encompasses a broad enough slice of the field to stimulate thinking about the possible applications of MR methods to specific research questions.

Entities:  

Mesh:

Year:  2009        PMID: 20559968     DOI: 10.1007/s12265-008-9084-3

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN: 1937-5387            Impact factor:   4.132


  67 in total

1.  Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting humans with 13C NMR.

Authors:  D L Rothman; I Magnusson; L D Katz; R G Shulman; G I Shulman
Journal:  Science       Date:  1991-10-25       Impact factor: 47.728

2.  Determination of deoxymyoglobin changes during graded myocardial ischemia: an in vivo 1H NMR spectroscopy study.

Authors:  W Chen; J Zhang; M H Eljgelshoven; Y Zhang; X H Zhu; C Wang; Y Cho; H Merkle; K Uĝurbil
Journal:  Magn Reson Med       Date:  1997-08       Impact factor: 4.668

3.  Relation between work and phosphate metabolite in the in vivo paced mammalian heart.

Authors:  R S Balaban; H L Kantor; L A Katz; R W Briggs
Journal:  Science       Date:  1986-05-30       Impact factor: 47.728

4.  Dynamic 13C NMR analysis of pyruvate and lactate oxidation in the in vivo canine myocardium: evidence of reduced utilization with increased work.

Authors:  D P Rath; H Zhu; X Tong; Z Jiang; R L Hamlin; P M Robitaille
Journal:  Magn Reson Med       Date:  1997-12       Impact factor: 4.668

5.  Mechanism by which metformin reduces glucose production in type 2 diabetes.

Authors:  R S Hundal; M Krssak; S Dufour; D Laurent; V Lebon; V Chandramouli; S E Inzucchi; W C Schumann; K F Petersen; B R Landau; G I Shulman
Journal:  Diabetes       Date:  2000-12       Impact factor: 9.461

Review 6.  Cellular mechanisms of insulin resistance in humans.

Authors:  G I Shulman
Journal:  Am J Cardiol       Date:  1999-07-08       Impact factor: 2.778

Review 7.  Cardiac magnetic resonance spectroscopy: potential clinical applications.

Authors:  S Neubauer
Journal:  Herz       Date:  2000-06       Impact factor: 1.443

8.  Three-dimensional MR mapping of angiogenesis with alpha5beta1(alpha nu beta3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model.

Authors:  Anne H Schmieder; Shelton D Caruthers; Huiying Zhang; Todd A Williams; J David Robertson; Samuel A Wickline; Gregory M Lanza
Journal:  FASEB J       Date:  2008-08-12       Impact factor: 5.191

Review 9.  MR in mouse models of cardiac disease.

Authors:  Frederick H Epstein
Journal:  NMR Biomed       Date:  2007-05       Impact factor: 4.044

10.  Impaired net hepatic glycogen synthesis in insulin-dependent diabetic subjects during mixed meal ingestion. A 13C nuclear magnetic resonance spectroscopy study.

Authors:  J H Hwang; G Perseghin; D L Rothman; G W Cline; I Magnusson; K F Petersen; G I Shulman
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

View more
  1 in total

1.  A multi-center preclinical study of gadoxetate DCE-MRI in rats as a biomarker of drug induced inhibition of liver transporter function.

Authors:  Anastassia Karageorgis; Stephen C Lenhard; Brittany Yerby; Mikael F Forsgren; Serguei Liachenko; Edvin Johansson; Mark A Pilling; Richard A Peterson; Xi Yang; Dominic P Williams; Sharon E Ungersma; Ryan E Morgan; Kim L R Brouwer; Beat M Jucker; Paul D Hockings
Journal:  PLoS One       Date:  2018-05-17       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.